Krishna Ventures Ltd vs Welcure Drugs Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 25, 2026

Key Highlights

The Latest Trading Price of Krishna Ventures Ltd is ₹ 57.95 as of 23 Oct 15:30 . The P/E Ratio of Krishna Ventures Ltd changed from 63.6 on March 2026 to 63.6 on March 2026 . This represents a CAGR of 0.00% over 1 yearsThe P/E Ratio of Welcure Drugs & Pharmaceuticals Ltd changed from 37.6 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 years The Market Cap of Krishna Ventures Ltd changed from ₹ 11.9 crore on March 2021 to ₹ 19.22 crore on March 2026 . This represents a CAGR of 8.32% over 6 yearsThe Market Cap of Welcure Drugs & Pharmaceuticals Ltd changed from ₹ 2.54 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The revenue of Krishna Ventures Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 9.36 crore. This represent the decline of -100% The revenue of Welcure Drugs & Pharmaceuticals Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Krishna Ventures Ltd for the Jun '26 is ₹ -0.02 crore as compare to the Mar '26 ebitda of ₹ 0.72 crore. This represent the decline of -102% The ebitda of Welcure Drugs & Pharmaceuticals Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ -49.86 crore. This represent the decline of -100% The net profit of Krishna Ventures Ltd changed from ₹ -0.25 crore to ₹ -0.05 crore over 9 quarters. This represents a CAGR of -51.10% The net profit of Welcure Drugs & Pharmaceuticals Ltd changed from ₹ -0.34 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The Dividend Payout of Krishna Ventures Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Welcure Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Krishna Ventures Ltd

Krishna Ventures Limited, was formerly incorporated in the name of Multifarious Trading and Agencies Limited in 1982.
The Company name was changed from Multifarious Trading and Agencies Limited to Krishna Ventures Limited with effect from 28 June, 2010.
The Company is presently engaged in construction and the provision of consultancy services in the Indian real estate sector.
Towards these ends, it identified key properties in Mumbai and adjoining areas to develop projects in the housing and commercial space.
It offers engineering solutions in the form of products and services in the area of HVAC (Heating, Ventilation & Air Conditioning) Steel Fabrication, Solar Structure and Pre Engineered Buildings to become a market leader. The Company established a manufacturing plant of HVAC systems for Railways & Defence sector which includes Roof mounted Packaged AC units for Passenger Coaches, Locomotive cabins & Guard cabin, Air Conditioning and Heating systems for Armoured vehicles etc and as an OEM supplier to Railways & Defence, it has been supplying these products to all the Rolling Stock manufacturing units of Indian Railways & to the Defence Ordnance Factories.

About Welcure Drugs & Pharmaceuticals Ltd

Incorporated on 4th June, 1992, Welcure Drugs And Pharmaceuticals Limited(WDPL) was promoted by D C Jain, Sanjeev Jain and Sandeep Jain.
The promoters have interests in other companies such as Paam Pharmaceuticals, Pioneer Products, Alirox Abrasives, A K Laboratories, etc. WDPL had come out with a Rs 4-cr public issue in Aug.'94 to part-finance the Rs 12 Crore project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary, A K Laboratories (AKL).
The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.'96 to finance its expansion programmes. Products of WDPL include bulk drugs such as ampicillin and trimethoprim, drugs intermediates and pharmaceutical formulations.
It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen.

FAQs for the comparison of Krishna Ventures Ltd and Welcure Drugs & Pharmaceuticals Ltd

Which company has a larger market capitalization, Krishna Ventures Ltd or Welcure Drugs & Pharmaceuticals Ltd?

Market cap of Krishna Ventures Ltd is 62 Cr while Market cap of Welcure Drugs & Pharmaceuticals Ltd is 22 Cr

What are the key factors driving the stock performance of Krishna Ventures Ltd and Welcure Drugs & Pharmaceuticals Ltd?

The stock performance of Krishna Ventures Ltd and Welcure Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Krishna Ventures Ltd and Welcure Drugs & Pharmaceuticals Ltd?

As of October 25, 2026, the Krishna Ventures Ltd stock price is INR ₹57.95. On the other hand, Welcure Drugs & Pharmaceuticals Ltd stock price is INR ₹0.18.

How do dividend payouts of Krishna Ventures Ltd and Welcure Drugs & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Krishna Ventures Ltd and Welcure Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.